TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention

Inclusion Criteria

• •Patients with breast cancer, expressing HER2-NEU (score +++ in ICH or ++ and amplification on FISH or CISH, SISH)
• •Visceral metastasis, only or multiple
• •First line metastasis treatment by Trastuzumab in association with chemotherapy
• •Good general conditions: OMS=\<2 or Karnofsky \>=70%
• •Age \> 18 years and \< 70 years
• •Life expectancy \>=3 mois
• •No Trastuzumab since more of 6 months
• •No cerebral metastasis (MRI)
• •Efficacy contraception for women with genital capacities
• •Consent signed by the patient